CRSP Relative Valuation
CRSP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRSP is overvalued; if below, it's undervalued.
Historical Valuation
CRISPR Therapeutics AG (CRSP) is now in the Fair zone, suggesting that its current forward PS ratio of 176.75 is considered Fairly compared with the five-year average of -13.14. The fair price of CRISPR Therapeutics AG (CRSP) is between 31.17 to 61.84 according to relative valuation methord.
Relative Value
Fair Zone
31.17-61.84
Current Price：58.19
Fair
-12.00
PE
1Y
3Y
5Y
-7.81
EV/EBITDA
CRISPR Therapeutics AG. (CRSP) has a current EV/EBITDA of -7.81. The 5-year average EV/EBITDA is -8.86. The thresholds are as follows: Strongly Undervalued below -39.65, Undervalued between -39.65 and -24.25, Fairly Valued between 6.54 and -24.25, Overvalued between 6.54 and 21.94, and Strongly Overvalued above 21.94. The current Forward EV/EBITDA of -7.81 falls within the Historic Trend Line -Fairly Valued range.
-6.87
EV/EBIT
CRISPR Therapeutics AG. (CRSP) has a current EV/EBIT of -6.87. The 5-year average EV/EBIT is -42.30. The thresholds are as follows: Strongly Undervalued below -374.73, Undervalued between -374.73 and -208.51, Fairly Valued between 123.92 and -208.51, Overvalued between 123.92 and 290.13, and Strongly Overvalued above 290.13. The current Forward EV/EBIT of -6.87 falls within the Historic Trend Line -Fairly Valued range.
176.75
PS
CRISPR Therapeutics AG. (CRSP) has a current PS of 176.75. The 5-year average PS is 231.99. The thresholds are as follows: Strongly Undervalued below -441.30, Undervalued between -441.30 and -104.66, Fairly Valued between 568.63 and -104.66, Overvalued between 568.63 and 905.28, and Strongly Overvalued above 905.28. The current Forward PS of 176.75 falls within the Historic Trend Line -Fairly Valued range.
-19.72
P/OCF
CRISPR Therapeutics AG. (CRSP) has a current P/OCF of -19.72. The 5-year average P/OCF is 53.81. The thresholds are as follows: Strongly Undervalued below -491.31, Undervalued between -491.31 and -218.75, Fairly Valued between 326.38 and -218.75, Overvalued between 326.38 and 598.94, and Strongly Overvalued above 598.94. The current Forward P/OCF of -19.72 falls within the Historic Trend Line -Fairly Valued range.
-19.69
P/FCF
CRISPR Therapeutics AG. (CRSP) has a current P/FCF of -19.69. The 5-year average P/FCF is 213.17. The thresholds are as follows: Strongly Undervalued below -1639.67, Undervalued between -1639.67 and -713.25, Fairly Valued between 1139.58 and -713.25, Overvalued between 1139.58 and 2066.00, and Strongly Overvalued above 2066.00. The current Forward P/FCF of -19.69 falls within the Historic Trend Line -Fairly Valued range.
CRISPR Therapeutics AG (CRSP) has a current Price-to-Book (P/B) ratio of 2.63. Compared to its 3-year average P/B ratio of 2.37 , the current P/B ratio is approximately 11.10% higher. Relative to its 5-year average P/B ratio of 2.76, the current P/B ratio is about -4.47% higher. CRISPR Therapeutics AG (CRSP) has a Forward Free Cash Flow (FCF) yield of approximately -5.92%. Compared to its 3-year average FCF yield of -6.35%, the current FCF yield is approximately -6.84% lower. Relative to its 5-year average FCF yield of -3.66% , the current FCF yield is about 61.48% lower.
2.63
P/B
Median3y
2.37
Median5y
2.76
-5.92
FCF Yield
Median3y
-6.35
Median5y
-3.66
Competitors Valuation Multiple
The average P/S ratio for CRSP's competitors is 258.13, providing a benchmark for relative valuation. CRISPR Therapeutics AG Corp (CRSP) exhibits a P/S ratio of 176.75, which is -31.52% above the industry average. Given its robust revenue growth of 47.67%, this premium appears sustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CRSP increased by 39.91% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 602.00K to 889.00K.
The secondary factor is the P/E Change, contributed 8.37%to the performance.
Overall, the performance of CRSP in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
EE
Excelerate Energy Inc
28.565USD
1.44%
MP
MP Materials Corp
61.849USD
3.39%
VAL
Valaris Ltd
51.19USD
-3.49%
CATY
Cathay General Bancorp
49.86USD
0.20%
HL
Hecla Mining Co
20.96USD
-5.88%
RNA
Avidity Biosciences Inc
72.26USD
0.01%
APAM
Artisan Partners Asset Management Inc
42.65USD
-1.43%
USLM
United States Lime & Minerals Inc
128.085USD
0.57%
SMPL
Simply Good Foods Co
19.4USD
1.31%
ESE
ESCO Technologies Inc
207.04USD
0.26%
Frequently Asked Questions
Is CRISPR Therapeutics AG (CRSP) currently overvalued or undervalued?
CRISPR Therapeutics AG (CRSP) is now in the Fair zone, suggesting that its current forward PS ratio of 176.75 is considered Fairly compared with the five-year average of -13.14. The fair price of CRISPR Therapeutics AG (CRSP) is between 31.17 to 61.84 according to relative valuation methord.
What is CRISPR Therapeutics AG (CRSP) fair value?
CRSP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of CRISPR Therapeutics AG (CRSP) is between 31.17 to 61.84 according to relative valuation methord.
How does CRSP's valuation metrics compare to the industry average?
The average P/S ratio for CRSP's competitors is 258.13, providing a benchmark for relative valuation. CRISPR Therapeutics AG Corp (CRSP) exhibits a P/S ratio of 176.75, which is -31.52% above the industry average. Given its robust revenue growth of 47.67%, this premium appears sustainable.
What is the current P/B ratio for CRISPR Therapeutics AG (CRSP) as of Jan 07 2026?
As of Jan 07 2026, CRISPR Therapeutics AG (CRSP) has a P/B ratio of 2.63. This indicates that the market values CRSP at 2.63 times its book value.
What is the current FCF Yield for CRISPR Therapeutics AG (CRSP) as of Jan 07 2026?
As of Jan 07 2026, CRISPR Therapeutics AG (CRSP) has a FCF Yield of -5.92%. This means that for every dollar of CRISPR Therapeutics AG’s market capitalization, the company generates -5.92 cents in free cash flow.
What is the current Forward P/E ratio for CRISPR Therapeutics AG (CRSP) as of Jan 07 2026?
As of Jan 07 2026, CRISPR Therapeutics AG (CRSP) has a Forward P/E ratio of -12.00. This means the market is willing to pay $-12.00 for every dollar of CRISPR Therapeutics AG’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for CRISPR Therapeutics AG (CRSP) as of Jan 07 2026?
As of Jan 07 2026, CRISPR Therapeutics AG (CRSP) has a Forward P/S ratio of 176.75. This means the market is valuing CRSP at $176.75 for every dollar of expected revenue over the next 12 months.